Encap Drug Delivery, a provider of development and manufacturing services to the pharmaceutical industry, has received US and Europe patents for DuoCap capsule delivery system.
DuoCap is a single oral dosage unit that comprises a capsule-in-a-capsule and offers therapeutic applications.
Encap claimed that the patented Duocap technology can provide protection for clients interested in novel line-extension formulations for drugs coming to the end of their patent life.
Encap said that, currently, pharmaceutical companies are using DuoCap delivery system in two probiotic combination products which are marketed worldwide. The system is also being used by the companies for products in clinical development.
Encap has recently signed a development and licensing agreement with a US company to develop a dual release dosage form of a drug.
Robbie Stewart, director of sales and marketing at Encap, said: “The issuance of these patents is an important achievement in the strengthening of Encap’s Intellectual Property portfolio. DuoCap was initially developed for use with probiotic treatments but now has huge potential for the delivery of many pharmaceutical active agents requiring controlled release.
“Another real advantage is the flexibility of our manufacturing process. Encap is able to manufacture DuoCap for clinical or proof-of-concept studies right through to full scale commercial volumes”